DDIAS knockdown caused growth inhibition of lung cancer cells through STAT3 inactivation by PTPRM, suggesting DDIAS as a potential therapeutic target in aberrant STAT3-activated lung cancer. This evidence concerns the gene PTPRM and lung cancer.